David W. Boyer, the Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Excessive hair growth can be embarrassing and frustrating. Learn the underlying causes of unwanted hair growth in women and ...

(Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

Advances in genetic testing, enable the identification of genetic causes even before symptoms appear, allowing for timely ...

Pratishtha Sharma, representative of PGIMER, informed that over the next three years, nearly 30,000 antenatal care (ANC) women in Moga will be screened for HbA2 (hemoglobin) levels using ...

Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant in the treatment ...

Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in ...

Conditions tested include cystic fibrosis, congenital adrenal hyperplasia and other rare genetic conditions. Acting Victorian Health Minister Ingrid Stitt said early testing was an important tool for ...

Conditions tested include cystic fibrosis, congenital adrenal hyperplasia and other rare genetic conditions. Acting Victorian Health Minister Ingrid Stitt said early testing was an important tool for ...